

Attorney Docket No. P33037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Damiani et al.	June 9, 2008
Serial No.:	10/511,769	Group Art Unit No.: 1625
Filed:	May 2, 2005	Examiner: C. C. Chang
For:	COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY	

Information Disclosure Statement Under 37 C.F.R. §1.97(c)


The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 10/511,769
Group Art Unit No.: 1625

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 2705023
Facsimile (610) 270-5090
N:\DMF\cases\P33037\IDS_FEE_REQUIRED.doc